Business Context and Reporting Period
This Form 8-K filing by Akebia Therapeutics, Inc. covers the period ending September 15, 2016. The report addresses a corporate governance event regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the departure of Anupam Dalal, M.D., from the Board of Directors. Dr. Dalal resigned effective September 16, 2016, due to a change in his job responsibilities. Following this resignation, the Board consists of eight directors.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or discussion of risks, contingencies, or unusual items. Management commentary is limited to acknowledging Dr. Dalal's years of service and contributions to the Company.
Key Facts for Investor Verification
- Anupam Dalal, M.D., resigned from the Board of Directors effective September 16, 2016.
- The resignation was accepted by the Board on September 15, 2016.
- The Board size is reduced to eight directors following the departure.
- The stated reason for resignation is a change in Dr. Dalal's job responsibilities.
- No financial data or operational updates are included in this specific filing.